Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses concerns about potential cognitive and emotional effects of finasteride, with the original poster planning to monitor their cognitive performance while using the treatment. A user responds that most people do not experience cognitive shifts, though some report subtle changes.

Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.

A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

Hair loss treatments, ranging from topical minoxidil and finasteride to taking hormones such as estradiol or nandrolone, as well as a controversial suggestion of an orchiectomy. A hair system is also mentioned as an alternative solution.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

A user shares their positive experience using the Rootique Dou applicator with 0.005% finasteride, noting it effectively delivers the product without greasiness and helps with hair regrowth without side effects. Another user reports regrowth using low-dose finasteride from ULO, while avoiding tretinoin due to skin irritation.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The conversation is about enhancing dermarolling for hair loss by using topical peptides like tb-500 or GHK-Cu to aid in healing and hair growth, and whether anyone has experienced significant results from this method.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.